Medivation Inc (MDVN)
Quote as of 9:47 AM ET 07/29/2010
| Exchange: |
NASDAQ GM |
| Last: |
9.43 |
| Change: |
($0.01) |
| Percent Change: |
-0.11 |
| Volume: |
6,954 |
Medivation, Inc. is a biopharmaceutical company. The Company focuses on the development of small molecule drugs to treat serious diseases. The Company?s product candidates in clinical development are dimebon (latrepirdine), which is in Phase III development for the treatment of Alzheimer?s disease and Huntington disease, and MDV3100, which is in Phase III development for the treatment of castration-resistant prostate cancer. Its dimebon program is partnered with Pfizer Inc. (Pfizer) and its MDV3100 program is partnered with Astellas Pharma Inc. (Astellas).
|
|
|